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Background: Labisia Pumila var. alata (LPva) has shown potential as an alternative to estrogen replacement
therapy (ERT) in prevention of estrogen-deficient osteoporosis. In earlier studies using postmenopausal model, LPva
was able to reverse the ovariectomy-induced changes in biochemical markers, bone calcium, bone
histomorphometric parameters and biomechanical strength. The mechanism behind these protective effects is
unclear but LPva may have regulated factors that regulate bone remodeling. The aim of this study is to determine
the bone-protective mechanism of LPva by measuring the expressions of several factors involved in bone formative
and resorptive activities namely Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor kappa-B Ligand
(RANKL), Macrophage-Colony Stimulating Factor (MCSF) and Bone Morphogenetic Protein-2 (BMP-2).
Methods: Thirty-two female Wistar rats were randomly divided into four groups: Sham-operated (Sham),
ovariectomized control (OVXC), ovariectomized with Labisia pumila var. alata (LPva) and ovariectomized with ERT
(Premarin®) (ERT). The LPva and ERT were administered via daily oral gavages at doses of 17.5 mg/kg and 64.5 μg/kg,
respectively. Following two months of treatment, the rats were euthanized and the gene expressions of BMP-2, OPG,
RANKL and MCSF in the femoral bones were measured using a branch - DNA technique.
Results: The RANKL gene expression was increased while the OPG and BMP-2 gene expressions were reduced in the
OVXC group compared to the SHAM group. There were no significant changes in the MCSF gene expressions among
the groups. Treatment with either LPva or ERT was able to prevent these ovariectomy-induced changes in the gene
expressions in ovariectomized rats with similar efficacy.
Conclusion: LPva may protect bone against estrogen deficiency-induced changes by regulating the RANKL, OPG
and BMP-2 gene expressions.
Keywords: Labisia pumila, Postmenopausal osteoporosis, Estrogen, OPG, BMP-2, RANKL, MCSFBackground
Osteoporosis is defined as a systemic skeletal disease that
is characterized by low bone mass and micro-architectural
deterioration of bone tissue, with a consequent increase in
bone fragility and susceptibility to fracture [1]. According
to the World Health Organization [2], osteoporosis occurs
when the bone mineral density falls more than 2.5
standard deviations (SD) below the standard reference* Correspondence: anazrun@yahoo.com
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reproduction in any medium, provided the orfor maximum bone mineral density of young adult fe-
males. The bone mass in females begins to decline
slowly after the age of 35 to 40, followed by a phase of
dramatic bone loss after menopause. This is due to es-
trogen deficiency which occurs naturally with aging or
by surgical ovariectomy.
By 50 years of age, the bone mass in women is only two-
thirds of that in men [3]. The relatively lower bone mass in
women is due to a combination of lower peak bone mass
and faster rate of bone loss. This leads to higher incidence
of osteoporosis in elderly women compared to men [4].
Osteoporosis should be managed appropriately as statisticsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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old suffered an osteoporotic fracture during their life-
time [5].
Estrogen Replacement Therapy (ERT) is one of the main
form of treatment and prevention of postmenopausal
osteoporosis. Estrogen given alone or in combination with
progesterone is able to prevent postmenopausal osteopor-
osis effectively [6]. Estrogen binds to its receptors on the
osteoclast surface, causing the release of chemical media-
tors which led to reduction of osteoclastic activity and in-
hibition of bone resorption [7].
The “Women’s Health Initiative Study” found that
women who took ERT have slightly higher rates of ovarian
cancer, breast cancer, heart attack, thromboembolism,
stroke, and Alzheimer’s disease [8-10]. These negative re-
ports on the serious adverse-effects of ERT have led to
many postmenopausal women searching for available al-
ternatives for their postmenopausal symptoms. These
have also paved way for missions to discover alternative
anti-osteoporotic agents that are comparable in effective-
ness to estrogen but with minimal adverse effects. Several
potential alternative agents were discovered including soy
[11], blueberry [12], Achyranthes bidentata [13] and
tocotrienol [14]. Recently, Labisia pumila var. alata
(LPva), a herb used for women’s health, was found to pro-
duce beneficial effects similar to estrogen on bone bio-
markers in postmenopausal osteoporosis animal model
[15]. These bone protective effects were further confirmed
by bone histomorphometric analysis [14-16] and bone
biomechanical strength [15-17].
Labisia Pumila (LP), a plant from the family of
Myrinaceae is a popular herb in Malaysia, Indonesia and
Indo-China. There are three variants of Labisia pumila,
which are var. alata (LPva), var. pumila and var.
lanceolata [18]. In Malaysia, it is known locally as “Kacip
Fatimah” and the extract can simply be prepared by boil-
ing the leaves, roots or the whole plant in water and the
extract is taken orally [18,19]. Nowadays, various Labisia
pumila preparations are available commercially in the
forms of capsules or added to drinks. It is used exclu-
sively by women to shrink the uterus, facilitate labor,
and improve menstrual irregularities and as post-partum
medicine [19,20]. Its limited use by women for their
health supplements has led to the belief that it is a
phytoestrogen, a compound with similar chemical struc-
ture to estrogen [21]. Several studies have demonstrated
the estrogenic properties of LPva. It was found to inhibit
estradiol binding to antibodies raised against estradiol
[22] and exert a specific estrogenic effect on human
endometrial adenocarcinoma cells (Ishikawa-Var I line)
[23]. It mimicked estrogen action by preventing the
shrinkage of the uterus due to estrogen deficiency in
ovariectomized rats [22] and initiate lipolysis in adipose
tissue [24]. LPva was also found to down-regulate 11β-hydroxysteroid dehydrogenase-1 expressions in liver and
adipose tissues and also decrease serum corticosterone
levels in ovariectomized rats [25]. In terms of bone protec-
tion against estrogen deficiency, LP was reported to exert
estrogen-like effects on bone remodeling [15-17].
Bone remodeling involves a fine balance between bone
formation and resorption. Any disturbance to the bal-
ance between these two processes would lead to bone
pathology. There are several factors or cytokines known
to play important roles in bone remodeling. Bone re-
sorption is regulated by Receptor Activator of Nuclear
Factor kappa-B ligand (RANKL) and Osteoprotegerin
(OPG), which are produced by osteoblasts [26]. RANKL
binds to RANK receptors which are located on osteo-
clast precursors to promote differentiation into mature
osteoclasts and activate their bone resorptive activity
[27]. It was reported that administration of serum
RANKL to mice promoted osteoclast growth and activa-
tion, leading to osteoporosis [28]. OPG acts as anti-
resorptive decoy receptor by binding to RANKL and
preventing it from binding to RANK receptors. As a re-
sult, OPG inhibits osteoclast differentiation and its bone
resorptive activity. In a recent development, a fully hu-
man monoclonal antibody against RANKL was devel-
oped to inhibit osteoclast activity. This new agent
named denosumab is still under clinical trial as a new
anti-osteoporotic agent [29].
Osteoclastogenesis also requires Macrophage-Colony
Stimulating Factor (MCSF), which is also expressed by
osteoblasts. It binds to the MCSF receptors situated in
the osteoclasts and stimulates osteoclastogenesis, but the
mechanism involved is still unclear [30]. There are sev-
eral factors which are known to affect osteoblast activity
and differentiation. Among the important one is bone
morphogenetic protein-2 (BMP-2), which promotes
osteoblast differentiation and plays an important role in
bone repair and regeneration [31]. In summary, the dif-
ferentiation and activation of osteoclast are influenced
by the RANKL/OPG system and MCSF, while BMP-2
plays a key role in osteoblast differentiation. Estrogen
was able to maintain bone density by regulating the gene
expressions of these factors [32] and LPva may have
similar actions. To the best of our knowledge, there is
no study on the mechanism of LPva extract in pre-
venting bone loss due to estrogen deficiency. Therefore,
the aim of the study is to determine the molecular
mechanism of LPva in protecting bone against estrogen-




Thirty-two female Wistar rats, aged three months old
and weighing 200 to 250 grams, were used as the animal
Fathilah et al. BMC Complementary and Alternative Medicine 2013, 13:217 Page 3 of 7
http://www.biomedcentral.com/1472-6882/13/217model in this study. The rats were allowed to acclimatize
for a week before the start of the study. They were
housed two per cage, at normal room temperature with
adequate ventilation and normal 12-hour light-dark
cycle. All rats were allowed free access to water and food
(commercial laboratory rat’s food containing 0.97% cal-
cium, 0.85% phosphorus and 1.05 IU/g of Vitamin D3)
(Gold Coin, Selangor, Malaysia). They were randomly di-
vided into four main groups. The sham-operated group
(Sham) and the ovariectomized control group (OVXC)
were given oral gavages of deionized water (vehicle)
throughout the study. The treatment group was either
given LPva at the dose of 17.5 mg/kg (LPva group) or
Premarin® at the dose of 64.5 μg/kg (ERT group) via
daily oral gavages for the duration of 8 weeks. The ERT
group acted as the positive control group. The rats were
euthanized upon completion of the study and both fem-
ora dissected out and cleaned of any tissues. The ap-
proval for this study was obtained from the University
Animal Ethic Committee of Universiti Kebangsaan
Malaysia (PP/FAR/2009/NAZRUN/14 JULY/267-JULY
2009-MAY-2010).
Labisia pumila var. alata (LP) extract
The root extract of LPva (Batch No: KF071107) was pur-
chased from Phytes Biotek Sdn Bhd. (Malaysia), a Good
Manufacturing Practice (GMP) licensed manufacturer of
herbal products, in the form of a freeze-dried standardized
extract. All LPva extractions were performed at the factory
in Shah Alam, Selangor, Malaysia, using a patented high-
pressure water extraction process (US 7,132,117 B2). They
were filtered at 1 to 4 mm and freeze-dried without malto-
dextrin or lactose. The brownish powdered LPva extract
used in this study was similar to the extract used in previ-
ous studies by Fathilah et al. [16,17] and Nazrun et al.
[15]. This extract was also the same form used for human
consumption as health supplements. Phytochemical test-
ing of the LPva extract by the Forest Research Institute
Malaysia (FRIM) found the extract to contain flavonoids,
saponins and triterpenes. The LPva extract was dissolved
in deionised water and given to the LPva group via oral
gavages at the dose of 17.5 mg/kg rat weight at 9 am daily
for 8 weeks [15-17]. The Premarin® (Wyeth-Ayerst,
Canada) tablet containing 0.625 mg of conjugated estro-
gen was crushed, dissolved in deionised water and given to
the ERT group via oral gavages at the dose of 64.5 μg/kg
rat weight at 9 am daily for 8 weeks [15-17]. These doses
were chosen based from our previous studies, which have
demonstrated protective effects against estrogen-deficient
osteoporosis [15-17].
Gene expression measurements
Gene expressions were measured using branched DNA
(bDNA) technique as described by Fathilah et. al [33].The bDNA assay is a sandwich nucleic acid hybridization
method that uses bDNA molecules to amplify signals
from captured target RNA. Briefly, the femoral bones were
ground into a fine powder with a pestle and mortar with
the addition of liquid nitrogen. Proteinase K was added
to release the ribonucleic acid (RNA), which was then
prepared according to directions suggested by Panomics
(Fremont, CA) for analysis of mRNA expression using
the Panomics QuantiGene Plex 2.0 systems. The bDNA
method combines RNA signal amplification and micro-
spheres with unique fluorescent signatures to enable
quantitation of multiple mRNA targets simultaneously
in the same sample, without having the amplification
inaccuracies of RT-PCR (reverse transcriptase–polymerase
chain reaction). The method allows for discrimination
of highly homologous messages [34,35]. Specific oligo-
nucleotide capture and extender probe sets (3 per
target) annealed exclusively to each mRNA of interest
and the housekeeping mRNAs. They were designed
according to the unique sequences within each message
sequence. The housekeeping genes used in this study
were glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
glucuronidase-beta (Gusb) and hypoxanthine phosphori-
bosyltransferase-1 (HPRT1). Specific mRNA transcripts
were captured to specific fluorescent beads by hybri-
dization to capture probe-extender probe interactions.
The signal from each hybridized unit was amplified by at-
tachment of biotinylated label probes at multiple binding
sites on the complexes, which were in turn bound to
streptavidin-conjugated R-phycoerythrin (SAPE) to pro-
duce fluorescence. The fluorescent signals associated with
individual capture beads were read using a Luminex100 IS
system (Luminex Corp., Austin, TX, US) with the bead
signature designating RNA target and the SAPE signal
designating abundance. For each well, the total fluores-
cence from each individual bead type (corresponding to
individual mRNA species) minus the background fluores-
cence for that bead type was normalized to the geometric
mean of the fluorescence of the 3 housekeeping genes.
The normalized signals for individual mRNAs from tripli-
cate wells were averaged to yield a single value for each
mRNA species being measured.
Statistical analysis
The results were expressed as mean ± standard error
of the mean (SEM). The data analysis was performed
using the Statistical Package for Social Sciences software
(SPSS 19; SPSS, Chicago, IL, USA). The data were first
tested for normality using the Kolmogorov–Smirnov
test. For normally distributed data, the statistical tests
used were the analysis of variance (ANOVA), followed
by Tukey’s Honestly Significant Difference (HSD) test.
For data that were not normally distributed, Kruskal–
Wallis and Mann–Whitney tests were used.
Figure 2 Osteoprotegerin Gene Expression. Samples were
normalized to GAPD MFI (MedianFluorescence Intensity). Error bars
represent the standard deviations of the average responses. Values
were as mean ± SEM; p < 0.05 is considered significant. a indicates
significant difference compared to the Sham group. Sham (water
vehicle), OVXC (water vehicle), LPva (Labisia pumila var. Alata
17.5 mg/kg/day), ERT (Premarin 64.5 μg/kg/day).
Fathilah et al. BMC Complementary and Alternative Medicine 2013, 13:217 Page 4 of 7
http://www.biomedcentral.com/1472-6882/13/217Results
RANKL gene expressions
The RANKL gene expression of the femoral bones was
significantly higher in the OVXC group compared to
other groups. Treatment with ERT was able to prevent
the ovariectomy-induced elevation of RANKL gene ex-
pression, until it was at the same level as the Sham
group. LPva supplementation was also able to prevent
the ovariectomy-induced elevation of RANKL gene ex-
pression. There were no significant differences in the
RANKL gene expression levels between the Sham, ERT
and LPva groups (Figure 1).
OPG gene expressions
The OPG gene expression of the femoral bones was signifi-
cantly lower in the OVXC group compared to the other
groups. Treatment with ERT was able to prevent the
ovariectomy-induced reduction of OPG gene expression,
until it was at the same level as the Sham group. LPva sup-
plementation was also able to prevent the ovariectomy-
induced reduction of OPG gene expression. There were no
significant differences in the OPG gene expression levels
between the Sham, ERTand LPva groups (Figure 2).
MCSF gene expression
There were no significant changes in MCSF gene expres-
sions of the femoral bones for all the groups (Figure 3).
BMP-2 gene expression
The BMP-2 gene expression of the femoral bones was
significantly lower in the OVXC group compared to the
other groups. Treatment with ERT was able to preventFigure 1 RANKL Gene Expression. Samples were normalized to
GAPD MFI (MedianFluorescence Intensity). Error bars represent the
standard deviations of the average responses. Values were expressed
as mean ± SEM; p < 0.05 is considered significant. a indicates
significant difference compared to the Sham group. Sham (water
vehicle), OVXC (water vehicle), LPva (Labisia pumila var. Alata
17.5 mg/kg/day), ERT (Premarin 64.5 μg/kg/day).the ovariectomy-induced reduction of BMP-2 gene ex-
pression, until it was at the same level as the Sham group.
LPva supplementation was also able to prevent the
ovariectomy-induced reduction in BMP-2 gene expres-
sion. There were no significant differences in the BMP-2
gene expression levels between the Sham, ERT and LPva
groups (Figure 4).
Discussion
Hormone replacement therapy (HRT/ERT) has been used
for the treatment and prevention of postmenopausalFigure 3 BMP-2 gene expression. Samples were normalized to
GAPD MFI (MedianFluorescence Intensity). Error bars represent
the standard deviations of the average responses. Values were as
mean ± SEM; p < 0.05 is considered significant. a indicates significant
difference compared to the Sham group. Sham (water vehicle), OVXC
(water vehicle), LPva (Labisia pumila var. Alata 17.5 mg/kg/day), ERT
(Premarin 64.5 μg/kg/day).
Figure 4 MCSF Gene Expression. Samples were normalized to
GAPD MFI (MedianFluorescence Intensity). Error bars represent the
standard deviations of the average responses. Values were expressed
as mean ± SEM. P < 0.05 is considered significant. a indicates significant
difference compared to the Sham group. Sham (water vehicle), OVXC
(water vehicle), LPva (Labisia pumila var. Alata 17.5 mg/kg/day), ERT
(Premarin 64.5 μg/kg/day).
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effects (Ferguson, 2004) [36]. Multiple studies have
reported that women who took HRT have slightly higher
rates of thromboembolism, heart attack, breast cancer,
ovarian cancer, stroke, and Alzheimer’s disease [8-10].
LPva has potential as an alternative to ERT for the treat-
ment of postmenopausal osteoporosis. In terms of safety,
several toxicity studies have confirmed that LPva is safe
[37,38]. While, in terms of its action, LPva has demon-
strated phytoestrogenic properties [20,21]. In an earlier
study, LPva was found to reverse the bone biochemical
marker changes due to ovariectomy [15]. Following
that, a further study reported that LPva protected bone
from osteoporotic changes due to estrogen deficiency.
This was based on its ability to preserve the bone
histomophometric parameters of ovariectomised rats
[16]. These osteo-protective effects of LPva would be
beneficial if they are accompanied by improvement in
the bone strength, thus reducing the risk of fracture.
This was confirmed by a biomechanical study which
showed that supplementation of LPva in ovariectomised
rats resulted in stronger femoral bone [17].
Several mechanisms of the bone protective effects of
LPva were proposed. Other than acting as phytoestro-
gen, LPva may exert anti-inflammatory and anti-oxidant
effects [17]. There were reports that inflammation may
induce osteoporosis [39,40]. LPva may inhibit inflamma-
tion that may be responsible for osteoporosis by inhibiting
tumor necrosis factor (TNF)-α production and down-
regulating cyclooxygenase-2 expression [41].
Reactive oxygen species were shown to cause bone loss
by stimulating osteoclast differentiation [42] and pro-
moting osteoblast apoptosis [43]. LPva exhibited anti-oxidative properties as it contains flavanoids, ascorbic
acid, beta-carotene, anthocyanin and phenolic compounds
[44]. Beta-carotene was found to have the best correlation
with anti-oxidative capacities of LP, followed by flavonoids,
ascorbic acid, anthocyanin and phenolic content [45].
Flavonoids were confirmed by phytochemical screening to
be present in our LPva extract. It is a potent free radical
scavenger in oxidative stress-related diseases such as
osteoporosis and rheumatism [46]. Other potent anti-
oxidants such as vitamin E have also been shown to
protect bone against osteoporosis [14]. Therefore, the
anti-oxidative and anti-inflammatory properties of LPva
extract may have contributed to the effectiveness of this
medicinal plant in treating osteoporosis.
In the final pathway for pathogenesis of osteoporosis,
there will be an imbalance between bone formation by
osteoblast and bone formation by osteoclasts with the
latter getting the upper hand. RANKL/OPG system,
MCSF and BMP-2 played an important role in the regu-
lation of the osteoclastic and osteoblastic activities.
Therefore, their gene expressions were measured in this
study to better understand the mechanism of LPva. To
the best of our knowledge, this is the first report on the
molecular mechanism of LPv in preventing bone loss
due to estrogen-deficient osteoporosis.
The function of OPG is to block the binding of RANKL
to RANK receptors on committed pre-osteclastic cells
[47]. Therefore, OPG is a potent anti-osteoclastogenic
factor. Estrogen is known to stimulate production of
OPG, while, estrogen deficiency leads to down-regulation
of OPG [48]. As expected, in the present study, the OPG
gene expression of the ovariectomised control group was
found to be down-regulated. Both the LPva supplementa-
tion and ERT were able to revert back the OPG gene
expression to sham levels. This study has shown that
osteo-protective mechanism of LPva may be similar to
ERT i.e. via stimulation of OPG production.
Estrogen deficiency led to up-regulation of pro-
inflammatory cytokines such as TNF-α and interleukins
[49,50]. TNF is an important cofactor of bone resorption
as it supports osteoclasts activation mediated by RANKL
and c-Fms/MCSF. RANKL is a membrane-bound mol-
ecule of TNF ligand family which promotes osteoclasts
formation [51]. In the present study, LPva may share
similar mechanisms with ERT to protect bone as both
were able to down-regulate the RANKL gene expression
of ovariectomised rats.
This suggested a novel regulation of OPG and RANKL
by LPva, which may help us to understand the mecha-
nism of protection against estrogen-deficient bone loss.
Interestingly, phytoestrogens such as genistein were also
able to enhance osteoblastic OPG production through
ER-dependent mechanisms and concurrently suppress
RANKL gene expression which is associated with an
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phytoestrogenic element in LPva could be the reason for
these novel findings.
We did not find any significant change in the MCSF
gene expression after ovariectomy. An in vitro study of
human endometrial stromal cells found that MCSF pro-
duction was dose-dependently enhanced by the addition
of sex hormone [56]. However, in this study, both ERT
and LPva did not produce any significant changes in the
MCSF gene expression. This meant that M-CSF was not
affected in this model of osteoporosis.
BMP-2 plays an important role in bone repair and
regeneration [31]. The BMP-2 gene expressions in the
femora of ovariectomised rats were significantly in-
creased by both LPva and ERT until they were similar to
the sham level. Similar to our findings, Zhou et. al [57]
also found that estrogen was able to activate BMP-2
gene transcription. Estrogen has been shown to stimu-
late the differentiation and activity of osteoblasts [58,59]
and increase bone formation and bone mass in animal
models [60,61]. Based on our results, the increased
BMP-2 in LPva group was probably contributed by the
phytoestrogenic effects of LPva.
Conclusions
As a conclusion, LPva is comparable to ERT in regu-
lating OPG, RANKL and BMP-2 gene expressions of
ovariectomised rats. Therefore, LPva has potential as an
alternative to ERT for the treatment and prevention of
estrogen-deficient osteoporosis. LPva may also be taken
as supplements by postmenopausal women who are un-
comfortable with the risk of serious side-effects with ERT.
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